Table 3 Estimated total direct and indirect costs over 5  years

	HER2-/HR+	HER2+/HR+	HER2+/HR-	Triple negative	Overall population	Costs for overall population as % of total direct and indirect costs
Direct costs
Active treatment	32 082 923 €	78 101 997 €	47 942 420 €	13 324 066 €	171 451 406 €	36.5%
Toxicity management	1 970 091 €	897 285 €	552 383 €	941 347 €	4 361 107 €	0.93%
Diagnostic	4 010 272 €	1 332 949 €	825 517 €	1 223 233 €	7 391 971 €	1.57%
Medical follow-up	29 423 667 €	12 716 285 €	7 324 521 €	7 119 424 €	56 583 898 €	12.05%
Palliative/BSC costs	122 235 074 €	57 831 745 €	24 095 929 €	24 850 132 €	229 012 880 €	48.78%
Total direct costs	189 722 027 €	150 880 260 €	80 740 771 €	47 458 202 €	468 801 261 €	99.85%
Indirect costs	357 760 €	165 000 €	86 400 €	82 310 €	691 470 €	0.15%
Total direct and indirect costs	190 079 787 €	151 045 260 €	80 827 171 €	47 540 512 €	469 492 731 €	100.00%

BSC, best supportive care; HER2, human epidermal growth factor receptor 2; HR, hormonal receptor.